㈱リプロセル
2 known investors
ReproCELL develops regenerative medicine and cell therapies (including clinical-grade GMP-compliant iPS cells and iPS-derived exosomes) and supplies research reagents, media, genome-editing tools, and cell-processing contract services. It also offers clinical testing (such as HLA testing for organ transplants), mail-in hormone testing, and personal iPS cell creation and storage services for researchers, hospitals, CROs, and individuals.
BiotechDigital HealthLongevity
Investors · 2
Frequently asked questions
- What does ㈱リプロセル do?
- ReproCELL develops regenerative medicine and cell therapies (including clinical-grade GMP-compliant iPS cells and iPS-derived exosomes) and supplies research reagents, media, genome-editing tools, and cell-processing contract services. It also offers clinical testing (such as HLA testing for organ transplants), mail-in hormone testing, and personal iPS cell creation and storage services for researchers, hospitals, CROs, and individuals.
- Who are ㈱リプロセル's investors?
- ㈱リプロセル's investors include DBJ Capital, Sumitomo Mitsui Trust nvestment Co. Ltd..